2024
Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failure
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patternsPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2021
Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy
Raju SC, Peters GW, Decker RH, Park HS. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2021, 12: e110-e116. PMID: 34861443, DOI: 10.1016/j.prro.2021.11.006.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyPrimary lung tumorsSynchronous primary lung tumorsAdverse events gradeCommon Terminology CriteriaBody radiation therapyLung tumorsNew primaryTerminology CriteriaOverall survivalClinical outcomesLung cancerRadiation therapyEvents gradeEarly-stage primary lung cancerMedian progression-free survivalEffective doseDistant failure ratesLocal failure rateMedian overall survivalMedian total dosePrimary lung cancerProgression-free survivalPatterns of recurrenceNonmetastatic lung cancerOutcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood
Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s143-s144. DOI: 10.1016/j.ijrobp.2021.07.323.Peer-Reviewed Original ResearchProgression-free survivalSquamous cell carcinomaOverall survivalHigh-risk scoreRisk scoreDiscovery cohortValidation cohortPeripheral bloodRisk factorsNon-metastatic squamous cell carcinomaMethods Peripheral blood samplesWorse progression-free survivalShorter progression-free survivalPoor progression-free survivalNeck squamous cell carcinomaHPV-negative statusPEG tube insertionPost-treatment time pointsCompletion of radiotherapyHigher neutrophil countOral cavity cancerNeck cancer recurrenceAforementioned risk factorsPeripheral blood samplesClinicopathologic covariatesOptimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards modelEffect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Translational Lung Cancer Research 2021, 10: 3793-3806. PMID: 34733629, PMCID: PMC8512470, DOI: 10.21037/tlcr-21-632.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalObjective response rateSmall cell lung cancerOverall survivalThoracic radiotherapySubgroup analysisRT subgroupPlacebo-controlled phase 2 trialSmall cell lung cancer patientsCell lung cancer patientsPrevious thoracic radiotherapyPrior thoracic radiotherapyRelapsed SCLC patientsPhase 2 trialCell lung cancerLung cancer patientsOS benefitPFS benefitSCLC patientsPlacebo groupPlacebo armRT patientsCancer patientsControl rateAssociation of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexQuality of lifeHigher epigenetic age accelerationTreatment-related symptomsOverall survivalEpigenetic age accelerationRadiation therapyRisk factorsClinical characteristicsNeck cancerAge accelerationWorse overall survivalHuman papilloma virusFaster biological agingAdverse eventsDistant metastasisLifestyle factorsMass indexCancer outcomesBlood biomarkersPapilloma virusFunctional assessmentHigher HRPatientsLinear accelerator-based single-fraction stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy for intact and resected brain metastases up to 3 cm: A multi-institutional retrospective analysis.
Diamond BH, Jairam V, Zuberi S, Li JY, Marquis TJ, Rutter CE, Park HS. Linear accelerator-based single-fraction stereotactic radiosurgery versus hypofractionated stereotactic radiotherapy for intact and resected brain metastases up to 3 cm: A multi-institutional retrospective analysis. Journal Of Radiosurgery And SBRT 2021, 7: 179-187. PMID: 33898081, PMCID: PMC8055233.Peer-Reviewed Original ResearchIntracranial progression-free survivalLocal progression-free survivalSingle-fraction stereotactic radiosurgeryProgression-free survivalBrain metastasesSF-SRSOverall survivalStereotactic radiotherapyStereotactic radiosurgeryMulti-institutional retrospective analysisSignificant differencesResected Brain MetastasesLarge brain metastasesTime of treatmentIntact metastasesRetrospective analysisLocal controlMetastasisSimilar outcomesSurvivalPatientsRadiotherapyRadiosurgery
2020
Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
He Y, Song L, Wang H, Chen P, Liu Y, Sun H, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, Park HS, Pacheco JM, Tabbò F, Xu M, Dai J, He K, Yang Y, Zhou C, Group W. Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer. Advanced Science 2020, 8: 2003263. PMID: 33643802, PMCID: PMC7887584, DOI: 10.1002/advs.202003263.Peer-Reviewed Original ResearchFirst-line chemotherapyLung cancer patientsLong-term survivalNSCLC patientsCancer patientsLung cancerTherapeutic responseProgression-free survivalMolecular signaturesWhole-exome sequencingLine chemotherapySCLC patientsFree survivalWorse survivalHigh TMBTherapeutic decisionsResults HistologyMolecular subtypesPatientsChemotherapyDifferent subtypesSubtypesLimited biomarkersTissue samplesSurvival
2019
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma
Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeck DissectionNeoplasm MetastasisNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsProgression-Free SurvivalProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyConceptsProgression-free survivalInvolved lymph nodesDistant metastasisPatterns of failureLocoregional recurrenceLymph nodesHuman papillomavirus-positive oropharyngeal carcinomaMultivariate analysisEdition American Joint CommitteeRate of DMWorse progression-free survivalHigh DM rateDedicated clinical trialsAmerican Joint CommitteeCancer (AJCC) staging systemProportional hazards regressionExternal beam radiationOropharynx cancerFree survivalNeck dissectionOropharyngeal carcinomaOverall survivalDisease recurrenceIntraoperative brachytherapyOPC patients